Guangzhou Innogen Pharmaceutical Group Co Ltd (hkse:02591) Share Price

Company Profile

Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHN
https://www.innogenpharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
96

Recommended

Oracle’s cloud database business is riding the AI wave.

Frank Lee | 22 September 2025

We raise our earnings forecast 11% for next year.

Angus Hewitt, CFA | 22 September 2025

Our analysts think the recent wobble in revenue growth is cyclical, not structural.

Joseph Taylor | 22 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,137.80	14.90	0.16%
CAC 40	7,883.94	53.83	0.69%
DAX 40	23,602.67	75.62	0.32%
Dow JONES (US)	46,381.54	66.27	0.14%
FTSE 100	9,229.91	3.23	0.04%
HKSE	26,159.12	185.02	-0.70%
NASDAQ	22,788.98	157.50	0.70%
Nikkei 225	45,493.66	447.85	0.99%
NZX 50 Index	13,136.54	5.00	-0.04%
S&P 500	6,693.75	29.39	0.44%
S&P/ASX 200	8,845.90	14.30	0.16%
SSE Composite Index	3,821.83	6.74	-0.18%